Managing the challenge of chemically reactive metabolites in drug development
Year: 2011
Type: review
Source: Nature Reviews Drug Discovery
DOI: 10.1038/nrd3408
Authors: B. Kevin Park, Alan Boobis, Stephen Clarke, Chris E. P. Goldring, David Jones, J. Gerry Kenna, Craig Lambert, Hugh G. Laverty, Dean J. Naisbitt, Sidney Nelson, Deborah A. Nicoll-Griffith, R. Scott Obach, Philip Routledge, Dennis A. Smith, Donald J. Tweedie, Nico Vermeulen, Dominic P. Williams, Ian D. Wilson, Thomas A. Baillie
Institutions: University of Liverpool, Imperial College London, GlaxoSmithKline (United Kingdom), Medicines and Healthcare products Regulatory Agency, AstraZeneca (United Kingdom), University of Washington, Merck & Co., Inc., Rahway, NJ, USA (United States), Pfizer (United States), Cardiff University, University of Wales, Boehringer Ingelheim (United States), Vrije Universiteit Amsterdam
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1996935441